Deals
Parexel’s Owner Weighs Sale of Drug-Testing Company
- Pamplona Capital is also considering taking Parexel public
- Company could seek about $9 billion value including debt
Parexel offices in Durham, North Carolina.
Photographer: Tom Fuldner/ParexelThis article is for subscribers only.
The owner of Parexel International Corp., which helps drugmakers run clinical trials, is working with an adviser on a potential sale that could value the company at several billion dollars, according to people familiar with the matter.
Private equity firm Pamplona Capital Management is also considering taking Parexel public, said one of the people, who asked to not be identified because the matter isn’t public. It has drawn takeover interest from private equity firms and other companies, the people said.